Low-dose treatment cuts bleeds in kids with hemophilia A
Study finds Hemlibra improves quality of life for young children
Written by |
Preventive treatment with low-dose Hemlibra (emicizumab-KXWH) significantly reduced bleeding and improved quality of life in young children with hemophilia A, regardless of inhibitor status, a real-world study in China found.
But ultrasound scans showed signs of worsening joint health despite fewer clinically apparent bleeds, suggesting that lower doses may not fully protect against small, clinically silent joint bleeds.
“Low-dose [Hemlibra] effectively reduces bleeding and improves quality of life, supporting its feasibility in resource-limited settings,” the researchers wrote, though they highlighted a need to better understand the treatment’s long-term effects on joint health.
The study, “Effectiveness and Safety of Prophylactic Low-Dose Emicizumab in Young Children With Hemophilia A: A Multicenter Retrospective Study,” was published in aJHaem.
Typical treatment involves higher first dose
Hemophilia A is caused by a deficiency of the clotting protein factor VIII (FVIII), resulting in hemophilia symptoms such as prolonged and unusual bleeding after injuries or without an obvious cause. Recurrent bleeding into the joints can eventually cause irreversible damage.
Standard treatment involves factor replacement therapy, which supplies the body with functional FVIII to normalize clotting. However, some people, particularly those with severe hemophilia A, develop antibodies against replacement FVIII. Known as inhibitors, these antibodies can make factor replacement therapy less effective.
Hemlibra, approved in the U.S. for hemophilia A patients with or without inhibitors, is an antibody-based therapy that mimics key clotting functions of FVIII without containing FVIII itself. Given by injection under the skin, Hemlibra is typically given at a higher dose for the first month, followed by a lower maintenance dose.
“While clinical trials … confirm [Hemlibra] efficacy across ages and inhibitor status, real-world data on low-dose regimens in very young children remain scarce,” the researchers wrote.
To learn more, they retrospectively analyzed data from 26 children with hemophilia A who were treated at three hospitals in China’s Guangdong Province from 2019 to 2025. Twenty-five had severe disease, and one had moderate disease.
The children had a median age of 5.1 and started Hemlibra at a median age of 2.2; four were younger than 1 when treatment began. Most had previously received FVIII replacement therapy, while two had never been treated. Ten children (38.5%) had developed FVIII inhibitors. They were followed on Hemlibra for a median of 48 months, or four years.
Doses and dosing schedules were individualized, and only one child received the standard four-week loading regimen. The median maintenance dose, converted to a weekly equivalent to allow comparisons across regimens, was 0.81 mg/kg per week, about 46% lower than the standard weekly-equivalent dose used in pivotal clinical trials.
Bleeding fell substantially with treatment. The median annualized bleeding rate (ABR), or estimated number of bleeds per year, decreased significantly from 5.31 before Hemlibra to 0.6 during treatment. Significant reductions were also seen in spontaneous bleeds, from 1.61 to 0.15 per year; trauma-related bleeds, from 3.46 to 0.46; and joint bleeds, from 2.38 to 0.04.
The proportion of children with no bleeds increased from 15.4% before treatment to 38.5% with Hemlibra.
Still, 16 children experienced 57 breakthrough bleeds, including 21 major bleeds in seven children, most related to trauma. These were managed with one or two doses of FVIII or recombinant factor VIIa, a bypassing agent used to promote clotting, with no related adverse events reported.
Bleeding improved regardless of inhibitor status. Median ABR fell significantly, from 7.39 to 0.93 among the 10 children with inhibitors and from 4 to 0.4 among the 16 without inhibitors.
The researchers also measured Hemlibra’s FVIII-like clotting activity in 20 children. The median FVIII-equivalent activity was 7.7% with higher weekly Hemlibra doses significantly associated with greater activity. According to the researchers, this relationship could help guide more individualized dosing.
Health-related quality of life also improved. Mean scores on a hemophilia-specific questionnaire increased significantly from 57.23 before Hemlibra to 69.78 during treatment, with improvements seen regardless of inhibitors’ status.
Joint imaging, however, revealed a more complicated picture.
Among 20 children with ultrasound assessments, mean joint health scores increased significantly from 2.2 to 4.2, indicating worsening structural changes despite the significant reduction in clinically apparent joint bleeds.
The findings suggest “that current low-dose regimens may prevent clinical bleeds but not subclinical micro-bleeds,” the researchers wrote. “This supports the need for optimized dosing targets or enhanced joint monitoring in this vulnerable population.”
No blood clots or thrombotic microangiopathy, a serious condition involving damage and clots in small blood vessels, were reported during the study.
The study was limited by its small and diverse group of participants, retrospective design, and lack of a control group, the team noted. Still, they said, “low-dose [Hemlibra] prophylaxis is effective and safe in young children with hemophilia A, offering a feasible treatment option in resource-limited settings.”
“Future prospective studies should evaluate long-term joint outcomes with dose optimization strategies,” they added.
Leave a comment
Fill in the required fields to post. Your email address will not be published.